In this study, Soumerai and associates compare the impact of prescription payment limits on drug utilisation, hospital and nursing home admissions on Medicaid patients in New Hampshire, where a 3-prescription payment cap had been enacted, and Medicaid patients in New Jersey, where no cap existed. The authors hypothesise that a limit on prescription reimbursement would limit drug use, resulting in poorer quality healthcare, which in turn would lead to hospitalisation or admission to a nursing home.
The patient population studied (n = 411, New Hampshire; n = 1375, New Jersey) consisted of Medicaid recipients who: were enrolled in Medicaid for 10 months or more during a baseline year; were ~ 60 years of age; were enrolled in Medicare by the start of the payment cap; were white (necessitated by the absence of nonwhite patients in the New Hampshire cohort); were living in the community at baseline; had no nursing home claims during the 6 months before follow-up began; had an average of 3 or more prescriptions per month; had at least 1 prescription per quarter during the baseline year; received 8 or more 'core' medications from specific therapeutic classes used to treat diabetes, heart disease, chronic obstructive pulmonary disease and asthma, seizures, or conditions requiring anticoagulants during the baseline year. The two study groups were similar in age, gender, medication use, and the numbers of inpatient episodes occurring 6 months before the time of the cap.
Prescription procurement rates were used as a proxy for medication use. The investigators developed an index of standardised monthly doses for each 'core' medication, where one standard dose equalled the median number of milligrams of active ingredient per month as reported on New Hampshire and New Jersey Medicaid prescription claims. Using segmented time-series regression to analyse changes in prescription procurement, the investigators found no differences between the two populations before the payment limit was initiated. During the cap, purchases of standardised monthly doses decreased from 2.8 to 1.9 per patient in New Hampshire, while no change was seen in prescription procurement in New Jersey. After the payment limit was lifted, the authors report that the rate of prescriptions obtained rose toward base-line levels.
The rate of admission to hospitals and nursing homes in both states was. measured during a 5 month baseline period, during the 11 months when the prescription payment limit was in effect, and for II months after the limit was rescinded. During the baseline period, the proportion of study patients entering nursing homes was similar for both groups (2.3% in New Hampshire and 2.1 % in New Jersey). By the end of the cap period, 10.6% of New Hampshire patients and 6.6% of New Jersey patients had been admitted to nursing homes. A relative risk ratio for nursing home admission of 1.8 was reported for the New Hampshire cohort. Although risk ratios for the other time periods were not calculated, the authors state that the excess risk of new admissions ceased after the payment limit was rescinded.
The recipients were categorised by the number of selected chronic medications they had obtained in addition to the 'core' medications during baseline. No significant difference in the risk of nursing home admissions was seen in either state for patients receiving fewer than 3 additional medications. For patients taking 3 or more additional medications, a relative risk ratio of 2.2 was reported for the New Hampshire group. For the 37 New Hampshire patients admitted to a nursing home just before or during the cap, 57% stayed for I year or more. No lengths of stay were reported for New Jersey recipients.
The investigators reported no differences in the time to first inpatient hospital admission between the two study groups.
In their discussion, the investigators suggest that the increase in New Hampshire nursing home admissions occurring during the payment limit may have been a result of either a deterioration in patient health or a desire to maintain unlimited access to medication, since payment limits did not apply to institutionalised patients. Costs related to the additional nursing home days experienced by the study group were estimated to be approximately $US300000.
Commentary
This article is a significant contribution to the sparse body of literature that examines the relationship between health policy, pharmaceuticals, and patient outcomes. The link between the presence of a financial barrier to medications and nursing home admissions has been hypothesised by healthcare practitioners and the pharmaceutical industry. However, a careful examination of the study raises concerns about the strength of the conclusions.
First, while the cohorts chosen may be similar to one another, the inclusion criteria may be so restrictive that the cohorts are not representative of a sizeable group of the population. Sample size is a key concern, given the quasi-experimental design of the study. Within the cohorts is a group of individuals eligible for Medicaid who are under 65 years of age. Because these individuals are categorically eligible, they may be at higher risk for institutionalisation. The number of individuals aged 60 to 64 is not reported, nor is an analysis of the effect of age on admission rates provided. Without this information, alternative explanations for the findings become more plausible.
Second, the cohorts could have differed in parameters not measured in this study. Admission to a nursing home is a process that involves a variety of nonpatient factors (e.g. physician preferences, family preferences, admission criteria, support from family and friends, cultural differences) which may have influenced the experiences of the two states as much as prescription reimbursement. One may PharmacoEconomics 1 (3) 1992 argue that these factors did not account for different admission rates, since the percentage of patients admitted to nursing homes seems similar during the baseline year. However, a stronger argument could be made regarding the similarity of the populations if more data points (perhaps 24 months) were used to establish a baseline. This would provide greater assurance that the divergence of rates witnessed was due to the payment limit and was not due to a continuation of an existing trend.
The major finding of the study focuses on the difference in admission rates between New Hampshire and New Jersey patients at the end of the cap period. Because the New Hampshire cohort includes only 411 patients and the small percentages of admissions indicate an infrequently occurring event, the question must be posed as to how many patient admissions would make the admission rates identical. Our calculations indicate that if seventeen fewer admissions would have occurred in New Hampshire, the admission rates between the two states would have been identical. An even smaller decrease would be needed to reach a level of nonsignificance. The point here is that the study conclusions rest on the decisions of a handful of individuals.
The rationale provided by the investigators for the nursing home admissions seen in New Hampshire is not compelling. Deterioration of health appears to be unlikely, given the nonsignificant differences in hospital admissions. Given the stigma of entering a nursing home, the authors' argument that some patients may have sought admission in order to avoid the prescription cap also appears somewhat tenuous. Furthermore, not having medicines reimbursed is not equivalent to not receiving medications. Having others pay for medicines, stockpiling medications [a phenomenon suggested by a previous analysis of New Hampshire data (Soumerai et al. 1987) ), and receiving medication samples, are less obtrusive interventions than admission to a nursing home. Furthermore, if financial barriers were the sole reason for admissions, a decline in the proportion of institutionalised patients would be seen after the cap was lifted.
Failure to observe such a decline suggests that the reason for changes in admission rates may not be economic in nature and may not be associated with the cap.
From this study one could conclude that the prescription payment limit may have been instrumental in increasing nursing home admissions. The quasi-experimental design, identification of a questionably comparable and representative cohort, clear lack of sufficient data to establish baseline rates of institutionalisation, and a multitude of plausible alternative explanations strongly suggests that the conclusions are tentative at best. However, the appeal of the authors' conclusions to some healthcare constituencies raises the danger that broad generalisations will be voiced, and policy decisions may be influenced, by a study whose conclusions should be interpreted cautiously.
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Summary
Increasing attention is being focused on cost-effectiveness of healthcare. Costs continue to increase, and now $US 1 0 billion is spent annually in the care of hypertension patients in the US. It is an area where careful consideration of the factors involved can lead to more cost-effective and perhaps better care. There is at present great variation 219 in expenditure; for instance 2-fold variation in total costs and 3-fold variation in medication costs per patient year have been found among 32 Veterans' Association hypertension clinics. There is now widespread support for development of guidelines to rationalise and improve practice, however the acceptability to clinicians of such development, and the effects on practice patterns and patient outcome, remain to be established. The 1988 report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure represents a thoughtful effort to develop guidelines for hypertension management, although it is a pity that risk-benefit was not addressed more explicitly.
'The cost-effectiveness of treatment for hypertension depends on the pretreatment level of blood pressure, age and sex of the patient, presence of other cardiovascular risk factors, long term control of blood pressure, and the annual costs of treatment. Treatment of very mild hypertension (diastolic blood pressure 90 to 94mm Hg), even if the benefits do exceed the risks, does not appear to be particularly cost-effective. ' Opportunities to improve cost-effectiveness lie in five areas. First, it is important not to treat mild hypertension before repeated blood pressure measurements have been made, although in practice hypertension is sometimes treated on the basis of a single office diastolic blood pressure reading of 90 to 94mm Hg. Home blood pressure recording has the advantage of eliminating 'white coat' hypertension. Secondly, the cost-effectiveness of antihypertensive regimens varies widely, and has been calculated as $US 10 900 per year oflife saved for propranolol, $US 16 400 for hydrochlorothiazide and $US72 100 for captopril; i.e. ~-blockers and diuretics appear to be preferred provided they are well tolerated. Thirdly, promotion of compliance is important. Continuity of care, regular visits and reminders for defaulters are cost-effective measures. It is important to ensure that patients do not neglect treatment for financial reasons. Patients who attend follow-up and obtain drugs, but who do not keep to their drug regimen, increase cost-benefit ratios because they incur all costs but do not receive the full benefits. Fourthly, it is often possible
